CLINICAL TRIALS PROFILE FOR ABILIFY MAINTENA KIT
✉ Email this page to a colleague
All Clinical Trials for ABILIFY MAINTENA KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02146547 ↗ | European Long-acting Antipsychotics in Schizophrenia Trial | Completed | UMC Utrecht | Phase 4 | 2015-02-01 | Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission. Discontinuation of antipsychotic medication is by far the most important reason for relapse. A possible method to optimize medication adherence is to treat patients with long-term, depot medication rather than oral medication. However, despite its apparent "common sense" this approach has neither been universally accepted by practicing psychiatrists nor unequivocally demonstrated in clinical trials. Therefore, in this study we aim to investigate possible advantages of depot medication over oral antipsychotics in an independently designed and conducted, randomized, pragmatic trial. |
| NCT02472652 ↗ | Aripiprazole, Abilify Maintena Collaborative Clinical Protocol | Terminated | Otsuka America Pharmaceutical | Phase 4 | 2015-06-01 | Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful. |
| NCT02472652 ↗ | Aripiprazole, Abilify Maintena Collaborative Clinical Protocol | Terminated | Gazda, Thomas D., M.D., PC | Phase 4 | 2015-06-01 | Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABILIFY MAINTENA KIT
Condition Name
Clinical Trial Locations for ABILIFY MAINTENA KIT
Trials by Country
Clinical Trial Progress for ABILIFY MAINTENA KIT
Clinical Trial Phase
Clinical Trial Sponsors for ABILIFY MAINTENA KIT
Sponsor Name
